This study focuses on individuals with advanced or metastatic Non-small Cell Lung Cancer, which is a type of lung cancer that has spread to other parts of the body. The research specifically targets patients whose cancer cells contain a KRAS G12C mutation, a specific genetic change that helps the cancer grow. The purpose of the study is to evaluate the safety and how well different combinations of experimental medicines work for this specific condition.

Several different medications are being studied, which may be given alone or in combination with other treatments. These include MK-1084, an oral tablet, as well as patritumab deruxtecan and sacituzumab tirumotecan, which are administered through intravenous infusion, a method where medicine is delivered directly into a vein. Other possible treatments include cetuximab. Some participants may also receive corticosteroids, which are medicines used to reduce inflammation.

During the study, participants will receive different combinations of these medications to see how they affect the cancer. The research will monitor how the body reacts to the treatments and whether the cancer shrinks or stops growing. The course of the study involves regular medical monitoring to track the effects of the drugs and any side effects that may occur.